chr11-2147755-G-C

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate

The ENST00000643349.2(ENSG00000284779):​c.307C>G​(p.Gln103Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: not found (cov: 32)

Consequence


ENST00000643349.2 missense

Scores

3
15

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 1.04
Variant links:
Genes affected
IGF2-AS (HGNC:14062): (IGF2 antisense RNA) This gene is expressed in antisense to the insulin-like growth factor 2 (IGF2) gene and is imprinted and paternally expressed. It is thought to be non-coding because the putative protein is not conserved and translation is predicted to trigger nonsense mediated decay (NMD). Transcripts from this gene are produced in tumors and may function to suppress cell growth. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2015]
IGF2 (HGNC:5466): (insulin like growth factor 2) This gene encodes a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. A read-through INS-IGF2 gene exists, whose 5' region overlaps the INS gene and the 3' region overlaps this gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 0 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.08320752).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
INS-IGF2NR_003512.4 linkuse as main transcriptn.519C>G non_coding_transcript_exon_variant 4/7
IGF2-ASNR_028043.2 linkuse as main transcriptn.1157G>C non_coding_transcript_exon_variant 3/3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ENST00000643349.2 linkuse as main transcriptc.307C>G p.Gln103Glu missense_variant 2/5 P1
IGF2-ASENST00000381361.4 linkuse as main transcriptn.1152G>C non_coding_transcript_exon_variant 3/32

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
29
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsDec 17, 2021The c.460C>G (p.Q154E) alteration is located in exon 4 (coding exon 3) of the INS-IGF2 gene. This alteration results from a C to G substitution at nucleotide position 460, causing the glutamine (Q) at amino acid position 154 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.098
BayesDel_addAF
Benign
-0.058
T
BayesDel_noAF
Benign
-0.32
CADD
Benign
12
DANN
Benign
0.94
DEOGEN2
Benign
0.0074
.;T
Eigen
Benign
-0.89
Eigen_PC
Benign
-0.94
FATHMM_MKL
Benign
0.059
N
LIST_S2
Benign
0.32
T;T
M_CAP
Uncertain
0.15
D
MetaRNN
Benign
0.083
T;T
MetaSVM
Uncertain
-0.22
T
MutationAssessor
Benign
0.34
.;N
MutationTaster
Benign
1.0
N;N;N;N;N
PROVEAN
Benign
-0.34
.;N
REVEL
Benign
0.22
Sift
Uncertain
0.0020
.;D
Sift4G
Benign
0.19
.;T
Polyphen
0.0080
.;B
Vest4
0.099
MutPred
0.089
.;Gain of relative solvent accessibility (P = 0.0999);
MVP
0.34
MPC
0.50
ClinPred
0.064
T
GERP RS
0.22
Varity_R
0.065
gMVP
0.013

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

No publications associated with this variant yet.

Other links and lift over

hg19: chr11-2168985; API